Furthermore, new quantitative tools are needed to guide the design of ocular drug delivery systems. Ocular drug delivery group operates at University of Helsinki and University of Eastern Finland ...

Furthermore, with the addition of newly approved therapies that have longer durations of action, sustained drug delivery systems, and emerging novel therapies, it can be challenging to stay ...

The next time you need to take a prescription drug, taking it might be as easy ... Silicone-Based Hydrogels for Controlled Ocular Delivery of Ophthalmic Drugs," was published in ACS Applied ...

Miist Therapeutics, a physics-based developer of inhaled medicines, today announced $7M in seed funding from investors ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

ALPHARETTA, Ga. - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company with a market capitalization of $85.7 million focused on developing therapies for ocular diseases, has announced ...

MediPrint remains committed to bringing LL-BMT1 to market as a novel drug delivery platform for the treatment of glaucoma and ocular hypertension. The company expects to engage with the FDA in ...

The Global Implantable Drug Delivery Devices Market was valued at USD 26.7 Bn in 2023. It is expected to reach USD 57.1 Bn by 2033, with a CAGR of 8.1% ...

had begun a career in ocular biotherapeutic drug delivery, and Jeff Schuster (CTO) had already established himself as one of the top technical minds in inhalation drug delivery. With this funding ...